Saybrook Capital NC Has $6.91 Million Position in Kenvue Inc. (NYSE:KVUE)

Saybrook Capital NC boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.2% in the fourth quarter, Holdings Channel reports. The firm owned 323,480 shares of the company’s stock after purchasing an additional 18,783 shares during the period. Kenvue accounts for 1.8% of Saybrook Capital NC’s investment portfolio, making the stock its 15th biggest holding. Saybrook Capital NC’s holdings in Kenvue were worth $6,906,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of KVUE. Concurrent Investment Advisors LLC boosted its holdings in shares of Kenvue by 131.9% in the third quarter. Concurrent Investment Advisors LLC now owns 53,517 shares of the company’s stock valued at $1,238,000 after buying an additional 30,438 shares during the period. Graypoint LLC acquired a new position in Kenvue during the third quarter worth $233,000. Principal Financial Group Inc. boosted its holdings in Kenvue by 3.2% during the third quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company’s stock worth $54,690,000 after purchasing an additional 73,542 shares during the last quarter. CWA Asset Management Group LLC bought a new stake in Kenvue during the third quarter worth $307,000. Finally, Galvin Gaustad & Stein LLC bought a new stake in Kenvue during the third quarter worth $214,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on KVUE. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. UBS Group dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $23.75.

Kenvue Stock Performance

Shares of KVUE stock opened at $23.46 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.83 billion, a price-to-earnings ratio of 44.25, a PEG ratio of 2.62 and a beta of 1.25. The stock has a fifty day moving average of $21.64 and a 200 day moving average of $22.33. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.